Product Datasheet

RIPK3/RIP3 Antibody - BSA Free
NBP2-24588

Unit Size: 0.1 mg

Store at -20C. Avoid freeze-thaw cycles.

www.novusbio.com technical@novusbio.com

Publications: 28

Protocols, Publications, Related Products, Reviews, Research Tools and Images at:
www.novusbio.com/NBP2-24588

Updated 9/9/2025 v.20.1



NBP2-24588

RIPK3/RIP3 Antibody - BSA Free

Product Information	
Unit Size	0.1 mg
Concentration	1.0 mg/ml
Storage	Store at -20C. Avoid freeze-thaw cycles.
Clonality	Polyclonal
Preservative	0.05% Sodium Azide
Isotype	IgG
Purity	Immunogen affinity purified
Buffer	PBS
Target Molecular Weight	56.7 kDa

Product Description	
Description	Novus Biologicals Rabbit RIPK3/RIP3 Antibody - BSA Free (NBP2-24588) is a polyclonal antibody validated for use in IHC, WB, ICC/IF and IP. Anti-RIPK3/RIP3 Antibody: Cited in 27 publications. All Novus Biologicals antibodies are covered by our 100% guarantee.
Host	Rabbit
Gene ID	11035
Gene Symbol	RIPK3
Species	Human, Primate, Mouse (Negative)
Reactivity Notes	Chimpanzee (100%). This antibody is not suitable for testing of mouse RIP3. Human reactivity reported in multiple pieces of scientific literature.
Immunogen	RIPK3/RIP3 Antibody was made to a synthetic peptide (QEGPKDPEAWSRPQ) corresponding to amino acids 497-518 of human RIPK3/RIP3 was used as immunogen for this antibody (isoform CRA_a, 518 amino acids, NP_006862.2). This also corresponds to amino acids 298-311 of isoform CRA_b (GenBank: EAW66022.1).

Product Application Details	
Applications	Western Blot, Immunohistochemistry-Paraffin, Immunocytochemistry/ Immunofluorescence, Immunohistochemistry, Immunoprecipitation
Recommended Dilutions	Western Blot 3-7 ug/ml, Immunohistochemistry, Immunocytochemistry/ Immunofluorescence 1:20-1:500, Immunoprecipitation, Immunohistochemistry-Paraffin 10 ug/ml
Application Notes	Use in Immunoprecipitation reported in scientific literature. Use in Western Blot reported in multiple pieces of scientific literature.

Images

Immunohistochemistry-Paraffin: RIPK3/RIP3 Antibody [NBP2-24588] - Analysis of RIP3 using polyclonal RIPK3/RIP3 Antibody [NBP2-24588]. Human pancreas probed with RIPK3/RIP3 antibody at 10 ug/ml.	
Western Blot: RIPK3/RIP3 Antibody [NBP2-24588] - Representative western blot analysis of RIP1, RIPK3/RIP3, and beta-actin in WI-38 NCs and IR-SCs 24 h after incubation with Veh or 10 uM PL. A cell lysate of etoposide-treated Jurkat cells was used as a positive control. Image collected and cropped by CiteAb from the following publication (https://www.aging-us.com/article/101100/text) licensed under a CC-BY license.	
Immunocytochemistry/Immunofluorescence: RIPK3/RIP3 Antibody [NBP2-24588] - HeLa cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X TBS + 0.5% Triton X-100. The cells were incubated with RIPK3/RIP3 Antibody [NBP2-24588] at a 1:200 dilution overnight at 4C and detected with DyLight 488 (Green) at a 1:500 dilution. Alpha tubulin was used at a 1:1000 dilution as a co-stain and detected with DyLight 550 (Red) at a 1:500 dilution. Nuclei were detected with DAPI (Blue) at 2.0ug/ml in 1X PBS. Cells were imaged using a 40X objective.	
Western Blot: RIPK3/RIP3 Antibody [NBP2-24588] - Analysis of RIP3 using polyclonal RIPK3/RIP3 antibody [NBP2-24588]. Human tissue blot probed with 5 ug/ml of RIP3 antibody: 1) brain, 2) heart, 3) small intestine, 4) kidney, 5) liver, 6) lung, 7) skeletal muscle, 8) stomach, 9) spleen, 10) ovary, 11) testis, 12) placenta probed at 5 ug/ml, 13) Ramos cell lysate probed at 7 ug/ml. Theoretical molecular weight 56.7 kDa.	

Western Blot: RIPK3/RIP3 Antibody - BSA Free [NBP2-24588] - HOIP limits the activity of TRAIL□induced apoptosis□ & necroptosis□mediating signalling complexesControl & HOIP KO HeLa cells were treated with FLAG□Iz□TRAIL (500 ng/ml) for the indicated times. The TRAIL complex I was immunoprecipitated via anti□FLAG beads. Complex II was isolated by immunoprecipitating caspase□8 from complex I□depleted lysates. Western blot was performed using the indicated antibodies. * indicates unspecific bands.WT & HOIP□deficient TNF KO MEFs, pre□treated for 1 h with zVAD, were stimulated with iz□TRAIL (1 µg/ml) for the indicated times. FADD□containing complexes were immunoprecipitated & analysed by Western blot.Data information: See also Fig EV2. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/28258062), licensed under a CC-BY license. Not internally tested by Novus Biologicals.



Western Blot: RIPK3/RIP3 Antibody - BSA Free [NBP2-24588] - The catalytic activity of HOIP contributes to preventing TRAIL□induced apoptosis but is dispensable for preventing necroptosisLysates from control or HOIP KO K562 cells reconstituted w/ empty vector, HOIP WT or HOIP C885S analysed by WB.HOIP KO K562 cells reconstituted w/ empty vector, HOIP WT or HOIP C885S, pre□treated w/ zVAD and/or Nec□1s for 1 h as indicated, treated w/ iz□TRAIL (1 µg/ml) for 24 h. Percentage of cell death determined by flow cytometry after PI labelling (n = 5; mean ± SEM). *P < 0.05, **P < 0.01; statistics performed using ANOVA.Control & HOIP KO K562 cells reconstituted w/ empty vector, HOIP WT or HOIP C885S treated w/ iz□TRAIL (100 ng/ml) for the indicated times. Lysates analysed w/ the indicated antibodies.Lysates from TNF KO HOIP KO MEFs reconstituted w/ empty vector, HOIP WT or HOIP C885S analysed by WB.TNF KO HOIP KO MEFs reconstituted w/ empty vector, HOIP WT or HOIP C885S, pre□treated w/ zVAD & Nec□1s for 1 h as indicated, treated w/ iz□TRAIL (1 µg/ml) for 24 h. Percentage of cell death determined by flow cytometry after PI labelling (n = 4; mean ± SEM). *P < 0.05, ***P < 0.001; statistics performed using ANOVA.TNF KO HOIP KO MEFs reconstituted w/ empty vector, pre□treated w/ zVAD and/or the RIPK3 inhibitor GSK'872 for 1 h as indicated, treated w/ iz□TRAIL (1 µg/ml) for 24 h. Percentage of cell death determined by flow cytometry after PI labelling (n = 3; mean ± SEM). *P < 0.05; statistics performed using t□test.TNF KO HOIP KO MEFs reconstituted w/ empty vector, HOIP WT or HOIP C885S, pre□treated w/ zVAD for 1 h, treated w/ iz□TRAIL (1 µg/ml) for the indicated times. FADD□containing complexes immunoprecipitated & analysed by WB. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/28258062), licensed under a CC-BY license. Not internally tested by Novus Biologicals.



Publications

Rossmanith J, Krummeich J, Moser A et al. Targeting the Met-RIPK1 signaling axis to enforce apoptosis and necroptosis in colorectal cancer Cell Death & Disease 2025-10-20 [PMID: 41115877]

Mall R, Bynigeri RR, Karki R et al. Pancancer transcriptomic profiling identifies key PANoptosis markers as therapeutic targets for oncology NAR cancer 2022-12-01 [PMID: 36329783] (WB)

Kupka S. Regulation of the TNFR1-signalling complex by LUBAC and associated deubiquitinases Cell Death Differ 2020-04-02 [PMID: 32231246]

Binks AWD. The role of immunogenic cell death in oncolytic herpes simplex virus-1 infection of cancer cells Int J Mol Sci 2022-05-14 [PMID: 35563257]

Feoktistova M, Makarov R, Yazdi AS, Panayotova-Dimitrova D RIPK1 and TRADD Regulate TNF-Induced Signaling and Ripoptosome Formation International journal of molecular sciences 2021-11-18 [PMID: 34830347] (WB, Human)

Malireddi RKS, Karki R, Sundaram B et al. Inflammatory Cell Death, PANoptosis, Mediated by Cytokines in Diverse Cancer Lineages Inhibits Tumor Growth ImmunoHorizons 2021-07-21 [PMID: 34290111] (WB)

Liccardi G, Ramos Garcia L et al. RIPK1 and Caspase-8 Ensure Chromosome Stability Independently of Their Role in Cell Death and Inflammation. Mol Cell 2019-07-02 [PMID: 30598363] (PLA, Mouse)

Coordinated Ubiquitination and Phosphorylation of RIP1 Regulates Necroptotic Cell Death de Almagro MC, Goncharov T, Izrael-Tomasevic A et al. Cell Death Differ. [PMID: 27518435] (WB, Human)

Shrestha A, Mehdizadeh Gohari I, McClane BA RIP1, RIP3, and MLKL Contribute to Cell Death Caused by Clostridium perfringens Enterotoxin mBio 2019-12-17 [PMID: 31848291] (WB, Human)

Zinngrebe J, Schlichtig F, Kraus JM et al. Biomarker Profile for Prediction of Response to SMAC Mimetic Monotherapy in Pediatric Precursor B-Cell Acute Lymphoblastic Leukemia Int. J. Cancer 2019-11-20 [PMID: 31749151] (WB, Human)

DeSisto J, O'Rourke R, Bonney S et al. DPS-2: A Novel Dual MEK/ERK and PI3K/AKT Pathway Inhibitor with Powerful Ex Vivo and In Vivo Anticancer Properties Transl Oncol 2019-05-13 [PMID: 31096110] (WB, Human)

Podder B, Gutta C, Rozanc J et al. TAK1 suppresses RIPK1-dependent cell death and is associated with disease progression in melanoma Cell Death Differ. 2019-03-08 [PMID: 30850732] (WB, Human)

More publications at http://www.novusbio.com/NBP2-24588

Novus Biologicals USA
10730 E. Briarwood Avenue
Centennial, CO 80112
USA
Phone: 303.730.1950
Toll Free: 1.888.506.6887
Fax: 303.730.1966
nb-customerservice@bio-techne.com

Bio-Techne Canada
21 Canmotor Ave
Toronto, ON M8Z 4E6
Canada
Phone: 905.827.6400
Toll Free: 855.668.8722
Fax: 905.827.6402
canada.inquires@bio-techne.com

Bio-Techne Ltd
19 Barton Lane
Abingdon Science Park
Abingdon, OX14 3NB, United Kingdom
Phone: (44) (0) 1235 529449
Free Phone: 0800 37 34 15
Fax: (44) (0) 1235 533420
info.EMEA@bio-techne.com

General Contact Information
www.novusbio.com
Technical Support: nb-technical@bio-techne.com
Orders: nb-customerservice@bio-techne.com
General: novus@novusbio.com

Products Related to NBP2-24588

NBP2-33376H	Blue Marker Antibody (6F4-F6) [HRP]
HAF008	Goat anti-Rabbit IgG Secondary Antibody [HRP]
NB7160	Goat anti-Rabbit IgG (H+L) Secondary Antibody [HRP]
NBP2-24891	Rabbit IgG Isotype Control

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

For more information on our 100% guarantee, please visit www.novusbio.com/guarantee

Earn gift cards/discounts by submitting a review: www.novusbio.com/reviews/submit/NBP2-24588

Earn gift cards/discounts by submitting a publication using this product: www.novusbio.com/publications